Akari Therapeutics Files 8-K
Ticker: AKTX · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1541157
| Field | Detail |
|---|---|
| Company | Akari Therapeutics PLC (AKTX) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $2.5 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, corporate-history
Related Tickers: AKTX
TL;DR
Akari Therapeutics filed an 8-K on Oct 15, 2025, with financial updates.
AI Summary
Akari Therapeutics Plc filed an 8-K on October 15, 2025, reporting on financial statements and exhibits. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and is listed under the SIC code for Pharmaceutical Preparations.
Why It Matters
This filing provides updated information and exhibits related to Akari Therapeutics' financial status and corporate structure, which is crucial for investors and stakeholders to assess the company's current standing.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
- October 15, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of October 15, 2025.
When was Akari Therapeutics Plc incorporated?
Akari Therapeutics Plc was incorporated in England and Wales.
What were Akari Therapeutics Plc's previous names?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
What is Akari Therapeutics Plc's Standard Industrial Classification (SIC) code?
Akari Therapeutics Plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date for this 8-K report?
The filing date for this 8-K report is October 15, 2025.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-10-15 08:45:38
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $2.5 Million — ng titled "Akari Therapeutics Announces $2.5 Million Registered Direct Offering". The full t
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 20KB
- ex10-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-018091.txt ( ) — 274KB
- aktx-20251014.xsd (EX-101.SCH) — 4KB
- aktx-20251014_def.xml (EX-101.DEF) — 26KB
- aktx-20251014_lab.xml (EX-101.LAB) — 36KB
- aktx-20251014_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: October 15, 2025 By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: Chief Executive Officer